##common.pageHeaderLogo.altText##
DOI:
https://doi.org/10.57187/5062

Original article

Vol. 156 No. 6 (2026)

Metamizole-induced agranulocytosis: utilisation trends, pharmacovigilance signals and regulatory risk-minimisation in Switzerland

Cite this as:
Swiss Med Wkly. 2026;156:5062
Published
26.06.2026

Summary

 INTRODUCTION: The therapeutic role of metamizole (dipyrone) remains controversial because of the risk of metamizole-induced agranulocytosis, a very rare, idiosyncratic, life-threatening adverse reaction. We described utilisation, spontaneous reporting and recent regulatory actions in Switzerland.

METHODS: We estimated national metamizole utilisation as defined daily doses (DDD; WHO DDD 3 g/day) for 2014–2023, derived from aggregated national sales data; individual case safety reports (ICSR) of metamizole-induced agranulocytosis were retrieved from VigiBase (the WHO global safety database) for 2014–2024. Outputs included annual counts, fatal proportion and utilisation-normalised reporting (metamizole-induced agranulocytosis per million DDD); analyses were primarily descriptive.

RESULTS: Utilisation increased by ~79% during the analysed period with a formulation mix of 95.7% oral, 4.2% ampoules, 0.1% suppositories. Metamizole-induced agranulocytosis reports rose from 13 (2014) to 57 (2024), with year-to-year variability; the fatal proportion declined from 13.5% (2014–2018; 17/126) to 5.8% (2019–2023; 13/224) and 1.8% in 2024 (1/57). Utilisation-normalised reporting increased from 1.42 to 3.29 per million DDD (total), while fatal reports remained low and trended downward (mean 0.249 per million DDD, 2014–2023). Among Swiss fatal cases, methotrexate was co-reported as a concomitant drug in 39.5% (15/38) (extended fatal set 2011–2025; fatal ICSRs irrespective of onset year). Switzerland contributes a disproportionately high absolute number of cumulative metamizole-induced agranulocytosis reports.

REGULATORY ACTIONS: EMA and Swissmedic implemented strengthened warnings; Swissmedic additionally required a red-framed outer carton statement, clarified indications (second-line severe pain; refractory high fever) and advised avoiding concomitant methotrexate; a Direct Healthcare Professional Communication was issued.

CONCLUSION: Regulatory assessments by EMA and Swissmedic concluded that the benefits of metamizole continue to outweigh the risks, provided the drug is used appropriately, action is taken promptly at first symptoms and concomitant methotrexate is avoided. However, the number of reported cases of agranulocytosis underscores the known risk in the context of widespread use. Spontaneous reports reflect reporting intensity, not incidence; ongoing monitoring of risk-minimisation effectiveness is warranted.

References

  1. 1. Fendrich Z. [Metamizol—a new effective analgesic with a long history. Overview of its pharmacology and clinical use]. Cas Lek Cesk. 2000 Jul;139(14):440–4.
  2. 2. Bachmann F, Meyer Zu Schwabedissen HE, Duthaler U, Krähenbühl S. Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4-methylaminoantipyrine. Br J Clin Pharmacol. 2022 Feb;88(4):1885–96. 10.1111/bcp.15108
  3. 3. Bachmann F, Duthaler U, Meyer Zu Schwabedissen HE, Puchkov M, Huwyler J, Haschke M, et al. Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2. Clin Pharmacol Ther. 2021 Jun;109(6):1505–16. 10.1002/cpt.2141
  4. 4. Lutz M. Metamizole (Dipyrone) and the Liver: A Review of the Literature. J Clin Pharmacol. 2019 Nov;59(11):1433–42. 10.1002/jcph.1512
  5. 5. Gut S, Rauch M, Haschke M, Huber CA, Gaertner J, Schur N, et al. Use of metamizole and other non-opioid analgesics in Switzerland between 2014 and 2019: an observational study using a large health insurance claims database. Swiss Med Wkly. 2024;154(3535. https://doi.org/10.57187/s.3535.
  6. 6. Tomidis Chatzimanouil MK, Goppelt I, Zeissig Y, Sachs UJ, Laass MW. Metamizole-induced agranulocytosis (MIA): a mini review. Mol Cell Pediatr. 2023 Aug;10(1):6. 10.1186/s40348-023-00160-8
  7. 7. Klose S, Pflock R, König IR, Linder R, Schwaninger M. Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data. Naunyn Schmiedebergs Arch Pharmacol. 2020 Apr;393(4):681–90. 10.1007/s00210-019-01774-4
  8. 8. Huber M, Andersohn F, Sarganas G, Bronder E, Klimpel A, Thomae M, et al. Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol. 2015 Feb;71(2):219–27. 10.1007/s00228-014-1777-8
  9. 9. Rudin D, Roos NJ, Duthaler U, Krahenbuhl S. Toxicity of metamizole on differentiating HL60 cells and human neutrophil granulocytes. Toxicology. 2019;426(152254. https://doi.org/10.1016/j.tox.2019.152254.
  10. 10. Cismaru AL, Rudin D, Ibañez L, Liakoni E, Bonadies N, Kreutz R, et al. Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. Genes (Basel). 2020 Oct;11(11):1275. 10.3390/genes11111275
  11. 11. Cismaru AL, Grimm L, Rudin D, Ibanez L, Liakoni E, Bonadies N, et al. High-Throughput Sequencing to Investigate Associations Between HLA Genes and Metamizole-Induced Agranulocytosis. Front Genet. 2020;11(951. https://doi.org/10.3389/fgene.2020.00951.
  12. 12. Andrès E, Maloisel F, Zimmer J. The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis. Br J Haematol. 2010 Jul;150(1):3–8. 10.1111/j.1365-2141.2010.08104.x
  13. 13. Stammschulte T, Ludwig WD, Mühlbauer B, Bronder E, Gundert-Remy U. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012. Eur J Clin Pharmacol. 2015 Sep;71(9):1129–38. 10.1007/s00228-015-1895-y
  14. 14. Lübow C, Rotthauwe J, Behles C. Metamizol: schwerwiegende Nebenwirkungen – Update. Bulletin zur Arzneimittelsicherheit. 2022;4):24-8.
  15. 15. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index. 2025 [Available from: https://atcddd.fhi.no/atc_ddd_index/?code=N02BB02
  16. 16. Measures to minimise serious outcomes of known side effect with painkiller metamizole (EMA/407900/2024) [updated 6 December 2024. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/metamizole-containing-medicinal-products-0
  17. 17. DHPC – Novalgin. Metamizol Spirig HC, Minalgin, Novaminsulfon Sintetica, Metamizol-Mepha (metamizolum) 2025 [Available from: https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/health-professional-communication--hpc-/dhpc-metamizolum.html
  18. 18. Rote-Hand-Brief zu metamizolhaltigen Arzneimitteln: Wichtige Maßnahmen zur Minimierung der schwerwiegenden Folgen des bekannten Risikos für Agranulozytose 2024 [Available from: https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2024/rhb-metamizol.html?nn=591002
  19. 19. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006;29(5):385–96. 10.2165/00002018-200629050-00003
  20. 20. Molokhia M, Tanna S, Bell D. Improving reporting of adverse drug reactions: Systematic review. Clin Epidemiol. 2009;1(75-92. https://doi.org/10.2147/clep.s4775. doi: https://doi.org/10.2147/CLEP.S4775
  21. 21. Metamizol 2024 [Available from: https://richtlijnendatabase.nl/richtlijn/postoperatieve_pijn/kinderen_-_postoperatieve_pijn/medicamenteuze_interventies_kinderen/metamizol_-_postoperatieve_pijn_kinderen.html
  22. 22. Public Assessment Report - Dolamizol 250 mg and 500 mg tablets (metamizole sodium monohydrate): Medicines Evaluation Board (MEB) of the Netherlands; 2021 [Available from: https://www.geneesmiddeleninformatiebank.nl/pars/h124159.pdf